| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | YK 4-279 | GDSC1000 | pan-cancer | AAC | -0.064 | 0.1 |
| mRNA | PD173074 | GDSC1000 | pan-cancer | AAC | -0.059 | 0.1 |
| mRNA | XMD14-99 | GDSC1000 | pan-cancer | AAC | -0.055 | 0.1 |
| mRNA | narciclasine | CTRPv2 | pan-cancer | AAC | 0.054 | 0.1 |
| mRNA | ML239 | CTRPv2 | pan-cancer | AAC | -0.058 | 0.1 |
| mRNA | XAV-939 | GDSC1000 | pan-cancer | AAC | -0.057 | 0.1 |
| mRNA | PHA-793887 | GDSC1000 | pan-cancer | AAC | -0.047 | 0.1 |
| mRNA | KH-CB19 | CTRPv2 | pan-cancer | AAC | 0.071 | 0.1 |
| mRNA | Vandetanib | CCLE | pan-cancer | AAC | 0.071 | 0.1 |
| mRNA | WZ4002 | CTRPv2 | pan-cancer | AAC | 0.068 | 0.1 |